HAYWARD, Calif.--Lynx Therapeutics here has completed a $26.8 million private placement of common stock at $10 per share. Proceeds will go toward finishing development of the company's proprietary Massively Parallel Signature Sequencing technology and building capacity for its early commercial uses. Completion of the financing "predated by a few weeks the first results ever obtained from application of the technology to a real biological system," noted Sam Eletr, Lynx's chairman and CEO.